Novo Nordisk unveiled the full results of two Phase 3 trials for its experimental obesity and diabetes treatment, CagriSema, at the American Diabetes Association's annual meeting in Chicago. The 68-week trials confirmed up to 23% weight loss in obese adults and 16% in overweight type 2 diabetics, with notable improvements in blood sugar levels.

Key Data:

• Glycated hemoglobin ≤6.5%: Achieved by 73.5% of patients on CagriSema vs. 15.9% on placebo

• GI-related side effects: Reported by 79.6% of patients on CagriSema (mostly mild to moderate)

• Serious adverse events: 9.8% in the CagriSema group vs. 6.1% in placebo

• Dropouts due to side effects: 6% for CagriSema vs. 3.7% for placebo

Despite initial investor disappointment over topline results last month—which contributed to the CEO's departure—the detailed findings may renew confidence in the drug's metabolic benefits and regulatory potential.

Market Monitoring:

To evaluate the stock's sentiment and financial outlook following these disclosures, use the Price Target Summary for real-time updates on analyst forecasts and market expectations for Novo Nordisk (NVO).